Clinical analysis of Lacosamide monotherapy in the treatment of Children with Benign Epilepsy with Centro-Temporal Spikes_Journal of Epilepsy

Authors：

FENG Jun ,  TANG Jihong , ZHANG Bingbing , XIAO Xiao , SHI Xiaoyan , WANG Manli

Department of Neurology, the Children's Hospital Affiliated to Soochow University, Suzhou 215025, China;

Corresponding author：

TANG Jihong, Email: tjhzsh@126.com

Keywords：

Lacosamide; Epilepsy; Efficacy; Safety

DOI：

10.7507/2096-0247.20210078

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the clinical efficacy and safety of Lacosamide (LCM) monotherapy in treating Benign epilepsy with centro-temporal spikes (BECT) at children. Methods The present research included 57 children with BECT who were treated with LCM monotherapy in the Children's Hospital Affiliated to Soochow University from June 2020 to June 2021. Among them, 26 were males and 31 were females, with an average age of (7.5±2.3) years. Analyze the efficacy and adverse reactions of 1, 2, 4, 6, 9 and 12 months after LCM treatment. The starting dose of LCM was 2 mg/(kg·d); increased 2 mg/(kg·d) every seven days; and titrated up to 4 ~ 8 mg/(kg·d) in children with weight ≥30 kg and <50 kg; titrated up to 6 ~ 12 mg/(kg·d) in children with weight ≥11 kg and <30 kg.Result The total effective rate was 94.12%; the cumulative control rate after 12-month medication was 86.27%; and the retention rate was 89.47%. Those all showed a higher rate. Conclusion LCM is significantly effective to BECT with less adverse reactions and more safety. It has high clinical application value.

Citation： FENG Jun, TANG Jihong, ZHANG Bingbing, XIAO Xiao, SHI Xiaoyan, WANG Manli. Clinical analysis of Lacosamide monotherapy in the treatment of Children with Benign Epilepsy with Centro-Temporal Spikes. Journal of Epilepsy, 2021, 7(6): 477-480. doi: 10.7507/2096-0247.20210078 Copy

1.	Iapadre G, Balagura G, Zagaroli L, et al. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. Paediatr Drugs, 2018, 20(5): 429-453.
2.	Yang L, Gao L, Luan Y, et al. Different drug treat with central-temporal region spike wave of benign epilepsy in children. Journal Medical Forum, 2017, 38(9): 21-23.
3.	Verrotti A, Loiacono G, Coppola G, et al. Pharmacotherapy for children and adolescents with epilepsy. Expert Opin Pharmacother, 2011, 12(2): 175-194.
4.	Hoy SM. Lacosamide: A review in focal-onset seizures in patients with epilepsy. CNS drugs, 2018, 32(5): 473-484.
5.	Parisi P, Paolino MC, Raucci U, et al. Atypical forms of benign epilepsy with centrotemporal spikes(BECTS): How to diagnose and guide these children. A Practical/scientific approach. Epilepsy Behav, 2017, 6(75): 165-169.
6.	Liu N, Zhou T, Zhu JP, et al. Clinical feature and treatment strategy of benign childhood epilepsy with centrotemporal spikes. Chinese Pediatric Emergency Medicine, 2017, 24(3): 228-232.
7.	European Medicines Agency. Lacosamide: summary of product characteristics [EB/OL]. [2020-12-01]. ‘https://www.ema.europa.eu/medicines/human/EPAR/vimpat#product-infomation-section’.
8.	US FDA. Vimpat@(lacosamide): highlights of prescribing information [EB/OL]. [2020-11-01]. ‘https://www.vimpat.com/vimpat-prescribing-information.pdf?v=1525296747’.
9.	Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev, 2010, 13(1): 21-42.
10.	Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res, 2015, 110: 189-205.
11.	Farkas A, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal sei-zures. Neurology, 2019, 93(12): e1212-e1226.
12.	Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2017, 16(1): 43-54.
13.	Meschede C, Witt JA, Rademacher M, et al. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure, 2018, 58: 141-146.
14.	Biton V, Gil-nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults wilh partial onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(Pt.A): 119-127.
15.	Hong Z, Inoue Y, Liao W, et al. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study. Epilepsy Res, 2016, 127: 267-275.

1. Iapadre G, Balagura G, Zagaroli L, et al. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. Paediatr Drugs, 2018, 20(5): 429-453.
2. Yang L, Gao L, Luan Y, et al. Different drug treat with central-temporal region spike wave of benign epilepsy in children. Journal Medical Forum, 2017, 38(9): 21-23.
3. Verrotti A, Loiacono G, Coppola G, et al. Pharmacotherapy for children and adolescents with epilepsy. Expert Opin Pharmacother, 2011, 12(2): 175-194.
4. Hoy SM. Lacosamide: A review in focal-onset seizures in patients with epilepsy. CNS drugs, 2018, 32(5): 473-484.
5. Parisi P, Paolino MC, Raucci U, et al. Atypical forms of benign epilepsy with centrotemporal spikes(BECTS): How to diagnose and guide these children. A Practical/scientific approach. Epilepsy Behav, 2017, 6(75): 165-169.
6. Liu N, Zhou T, Zhu JP, et al. Clinical feature and treatment strategy of benign childhood epilepsy with centrotemporal spikes. Chinese Pediatric Emergency Medicine, 2017, 24(3): 228-232.
7. European Medicines Agency. Lacosamide: summary of product characteristics [EB/OL]. [2020-12-01]. ‘https://www.ema.europa.eu/medicines/human/EPAR/vimpat#product-infomation-section’.
8. US FDA. Vimpat@(lacosamide): highlights of prescribing information [EB/OL]. [2020-11-01]. ‘https://www.vimpat.com/vimpat-prescribing-information.pdf?v=1525296747’.
9. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev, 2010, 13(1): 21-42.
10. Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res, 2015, 110: 189-205.
11. Farkas A, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal sei-zures. Neurology, 2019, 93(12): e1212-e1226.
12. Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2017, 16(1): 43-54.
13. Meschede C, Witt JA, Rademacher M, et al. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure, 2018, 58: 141-146.
14. Biton V, Gil-nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults wilh partial onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(Pt.A): 119-127.
15. Hong Z, Inoue Y, Liao W, et al. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study. Epilepsy Res, 2016, 127: 267-275.

Next Article
Analysis of gene mutations and clinical features about a sleep-related hypermotor epilepsy family

Journal of Epilepsy

Clinical analysis of Lacosamide monotherapy in the treatment of Children with Benign Epilepsy with Centro-Temporal Spikes

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content